• Glutamine Metabolism as a Target in Liver Fibrosis

  2026-09-02

  The reference study identifies hepatic stellate cell glutaminolysis as a therapeutically relevant driver of liver fibrosis and establishes SIRT4 as an endogenous regulator of GDH activity. Its combination of pharmacological inhibition, SIRT4 modulation, and in vitro and in vivo validation provides a mechanistic framework for linking mitochondrial metabolism with fibrogenic cell behavior.

• CBD in Orofacial Inflammatory Pain: Mechanisms

  2026-09-02

  This 2026 Brain Research Bulletin study shows that cannabidiol (CBD) can reduce both nociceptive and pain-related affective abnormalities in mouse models through distinct peripheral and central endocannabinoid mechanisms. Its integrated behavioral, biochemical, and circuit-level design provides a useful framework for studying inflammatory pain, emotional comorbidity, and translational analgesia.

• Mechanisms of Cell Death in Heart Disease: Key Insights

  2026-09-01

  The reference review reframes cardiac injury by showing that apoptosis and necrosis are distinct but interconnected outcomes of regulated cellular pathways. Its central contribution is the recognition that a substantial subset of necrotic death can be actively controlled, creating a mechanistic basis for studying cell-death modulation in myocardial infarction and heart failure.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer

  2026-09-01

  A 2026 FASEB Journal study developed chemically modified p21 mRNA–loaded lipid nanoparticles for localized intravesical treatment of bladder cancer. The work links restoration of nuclear p21 to cell-cycle suppression, DNA-damage signaling, apoptosis, and tumor control in an orthotopic mouse model, while showing limited systemic distribution.

• Coumestrol, PMAIP1, and Ferroptosis in RA-FLS

  2026-08-31

  The reference study identifies a mechanistic link between Coumestrol treatment, TRIM3-dependent stabilization of mitochondrial PMAIP1, and ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. Its integrated phenotype and knockdown experiments suggest a useful framework for studying synoviocyte proliferation and inflammation, while the in vitro design limits direct therapeutic interpretation.

• TLS, TRAF2 Competition, and B-Cell Activation in ESCC

  2026-08-31

  A 2025 Cancer Gene Therapy study identifies tertiary lymphoid structures as an independent favorable prognostic feature in treatment-naïve esophageal squamous cell carcinoma and defines an IRF4-centered mechanism of B-cell activation. Its central mechanistic insight is that CD40 and STING compete for TRAF2, linking receptor signaling, STING ubiquitination and phosphorylation, non-canonical NF-κB activity, and TLS-associated immunity.

• AMG 9810: TRPV1 Antagonism Under Stress

  2026-08-30

  AMG 9810 is a selective TRPV1 antagonist for separating sensory calcium signaling from metabolic-stress adaptation. This article connects rigorous TRPV1 assay design with the AMPK–SQSTM1/NRF2 findings of a 2024 autophagy study while clearly defining the evidence limits.

• Human iPSC Hepatobiliary Organoids: Study Insights

  2026-08-29

  Wu et al. established a three-stage method for generating three-dimensional hepatobiliary organoids from human induced pluripotent stem cells without exogenous cells or genetic manipulation. The resulting structures combined hepatocyte-like and biliary functions, providing a platform for studying liver development, drug metabolism, and liver disease modeling.

• CHK1 Inhibition in ER/PR-Stratified Breast Cancer

  2026-08-28

  The reference study demonstrates that CHK1 inhibition has subtype-dependent effects in breast cancer: it enhances adriamycin sensitivity in ER−/PR−/HER2− disease but shows single-agent activity rather than chemosensitization in ER+/PR+/HER2− models. Its integrated database, drug-response, cell-cycle, apoptosis, and transcriptome analyses provide a framework for matching CHK1-targeted strategies to receptor status.

• α-Eudesmol Limits Ischemic Brain Injury via Cav2.1

  2026-08-28

  The reference study shows that α-eudesmol, an inhibitor of ω-agatoxin IVA-sensitive calcium channels, suppresses calcium-dependent glutamate release and reduces edema and infarction after focal cerebral ischemia in rats. Its value lies in connecting presynaptic P/Q-type channel pharmacology with acute ischemic neuroprotection, while also highlighting the selectivity limits of a small-molecule blocker.

• Decitabine Workflows for Cancer Epigenetics

  2026-08-27

  Decitabine enables controlled studies of DNMT1 inhibition, DNA hypomethylation, and tumor suppressor gene reactivation across hematologic and solid-tumor models. This workflow pairs dose–time design with molecular, phenotypic, and toxicity readouts so researchers can distinguish epigenetic priming from nonspecific cytotoxicity.

• In Situ TIL Therapy with Membrane-Anchored Anti-CD3

  2026-08-27

  The ACS Nano study introduces an in situ tumor-infiltrating lymphocyte strategy in which lipid nanoparticles deliver mRNA encoding a membrane-anchored anti-CD3 single-chain variable fragment to tumor-associated macrophages and tumor cells. This design combines local polyclonal T-cell activation with tumor-cell engagement and produces antitumor activity in B16F10 and MC38 models, including improved responses when paired with anti-PD-1 therapy.

• Ziprasidone Targets GOT1 in Pancreatic Cancer

  2026-08-26

  A 2022 Journal of Molecular Medicine study identified ziprasidone as a noncompetitive GOT1 inhibitor that disrupts glutamine metabolism, redox balance, and pancreatic ductal adenocarcinoma growth. Its combination of biochemical, cellular, genetic, metabolomic, and xenograft evidence supports GOT1 as a tractable metabolic target while leaving questions about selectivity and clinical translation unresolved.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-08-26

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is suited to blunt-ended products for cloning and sequencing, but not to workflows that require 3′-A overhangs or sticky ends.

• HBsAg Targets TBK1 to Evade Innate Immunity

  2026-08-26

  This 2025 Cell Death and Disease study identifies a direct mechanism by which hepatitis B surface antigen redirects TBK1 signaling away from IRF3-dependent type I interferon production and toward incomplete autophagy. The findings connect HBsAg-driven TBK1 dimerization, p62 phosphorylation, and SNAP29 suppression with HBV persistence, providing a mechanistic framework for studying viral immune evasion.

7887 records 1/526 page Next 12345 下5页 Last page